Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation.

Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation.

<h4>Background</h4>Hypercholesterolaemia is common in patients after cardiac transplantation. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol levels and subsequently the risk of cardiovascular event...

Full description

Bibliographic Details
Main Authors: Michael Kühl, Christian Binner, Joanna Jozwiak, Julia Fischer, Jochen Hahn, Alaeldin Addas, Boris Dinov, Jens Garbade, Gerhard Hindricks, Michael Borger
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0210373

Internet

https://doi.org/10.1371/journal.pone.0210373

Similar Items